Dr. Yu-Fang Hu currently serves as the CEO of the Genext Biopharm. Dr. Hu possesses extensive skills and knowledge in the Industrial Pharmaceutical field with over 25 years of experience in organizational development and management. From April 1999 to September 2023, he served as senior R&D Manager, Vice President, and then Senior Vice president in TTY Biopharm Co. Ltd., Taiwan, and one of key responsibilities is to develop the company's product line. It should be noted that he also established the liposome technology and long-acting microsphere injection platforms in TTY; and launched the AmBisome generic drug in the world, as well as obtained the global contract manufacturing project from Johnson & Johnson for Doxil product. Meanwhile, from 2019 to 2021, he served as the President & CEO of PharmaEngine Inc.; in addition, in 2017, founded EnhanX Biopharm Inc. in Taiwan and serves as Chairman.